1. Most Discussed
  2. Gainers & Losers

Prima BioMed announces second milestone payment for IMP701 program

Bookmark and Share
  1. July 17 (Reuters) - Prima BioMed

    • it will receive a second undisclosed significant clinical milestone payment from Novartis
    • payment based on collaboration and licensing agreement between companies, relating to Prima's imp701 lag-3 antibody
    Discuss this via PRR

Before making any financial decisions based on what you read, always consult an advisor or expert.

To read reuters' full disclaimer click here